LDALD - Overview: Lysosomal and Peroxisomal Disorders Newborn Screen, Blood Spot

Test Catalog

Test Name

Test ID: LDALD    
Lysosomal and Peroxisomal Disorders Newborn Screen, Blood Spot

Useful For Suggests clinical disorders or settings where the test may be helpful

First-tier newborn screen for the lysosomal disorders: Fabry, Gaucher, Krabbe, MPSI, Niemann-Pick types A and B, and Pompe (Glycogen storage disorder type II)


First-tier newborn screen for the peroxisomal disorder: X-linked adrenoleukodystrophy

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

Testing performed in the context of newborn screening only. For diagnostic testing, or at a clinical biochemical geneticist's discretion, testing may be changed to PLSD / Lysosomal and Peroxisomal Storage Disorders Screen, Blood Spot.


Lysosomal storage disorders are a diverse group of inherited diseases characterized by the intracellular accumulation of macromolecules leading to cell damage and organ dysfunction.


Peroxisomal disorders such as X-linked adrenoleukodystrophy are caused by a defect in a single peroxisomal enzyme/transporter, whereas Zellweger syndrome spectrum (ZSS) disorders are caused by peroxisome biogenesis defects.


Due to the improved outcomes associated with presymptomatic intervention, some states have recently added select lysosomal storage disorders and peroxisomal disorders to their newborn screening programs.


Additional biochemical or molecular testing is required to confirm a diagnosis if enzyme deficiency is detected by this screening test.

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

First-tier results will be reviewed and second-tier screening performed at a clinical biochemical geneticist's discretion at no additional charge. This minimizes the false-positive rate and maximizes the positive predictive value of screening for these lysosomal storage disorders.

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.


Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

LSD/X-ALD Newborn Screen, BS

Aliases Lists additional common names for a test, as an aid in searching

Acid Alpha-Glucosidase
Acid Beta-Glucosidase
Acid Maltase Deficiency
Adrenoleukodystrophy (ALD)
Alpha Galactosidase A
Anderson-Fabry Disease
Ceramide Trihexosidase
Cerebrosidase B-Galactosidase
Cerebrosidase Beta-Galactosidase
Fabry Disease
Gaucher Disease
Globoid Cell Leukodystrophy
Glucocerebrosidase Deficiency
Glycogen Storage Disease Type II (GSD II)
GSD II (Glycogen Storage Disease Type II)
Krabbe Disease
LSD Screen
Lysosomal Storage Disorder Screen
MPS IH (Hurler syndrome)
MPS IH/S (Hurler-Scheie syndrome)
MPS IS (Sheie syndrome)
Mucopolysaccharidosis type I
Newborn screening
Niemann-Pick Disease (NPD)
NPD (Niemann-Pick Disease)
Pompe Disease
Sphingomyelinase Deficiency
X-linked adrenoleukodystrophy (XALD)
Zellweger Spectrum Syndrome (ZSS)
Zellweger Syndrome